Dhampur Bio Organics Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
DBOL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.9 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dhampur Bio Organics reported a strong topline for Q1 FY26, with standalone revenue from operations rising about 29% year-on-year to ₹821.19 crore (vs ₹637.84 crore in Q1 FY25), driven by growth in sugar, biofuels & spirits, and country liquor segments. Consolidated revenue grew around 23% to ₹783.68 crore. However, the company swung to a standalone loss after tax of ₹19.37 crore (vs a profit of ₹1.11 crore a year ago) and a consolidated loss of ₹22.00 crore, with EPS turning negative at ₹(2.92) standalone and ₹(3.31) consolidated. Operating margin compressed sharply to -1.18% (standalone) from 3.46% a year ago, hit by higher raw material costs and excise duties. The board also appointed Grant Thornton Bharat LLP as the new Internal Auditor for FY25-26, replacing the previous internal auditor.
Strong revenue growth reflects expanding volumes, but the sharp swing to losses and a near-zero debt service coverage ratio (0.05x) suggest margin pressure and seasonal cost stress, which are negative near-term signals for shareholders. The stock may remain volatile until clarity on margin recovery and the upcoming ₹50 crore commercial paper repayment on August 12, 2025.